Literature DB >> 28988656

Thirty-Year Trends of Survival and Time-Varying Effects of Prognostic Factors in Patients With Metastatic Breast Cancer-A Single Institution Experience.

Bianca Rogoz1, Agathe Houzé de l'Aulnoit2, Alain Duhamel3, Denis Houzé de l'Aulnoit2.   

Abstract

BACKGROUND: Metastatic breast cancer is generally considered an incurable disease. In our study we aimed to detect a time trend of survival over the past 30 years and account for time-varying effects of the prognostic factors. PATIENTS AND METHODS: A total of 446 patients diagnosed with breast cancer at Saint Vincent de Paul Hospital, Lille, France between 1977 and 2013 who developed metastatic disease after a disease-free interval longer than 3 months and were followed-up for outcome. Data were analyzed using the Cox proportional hazards model and presented as hazard ratios (HRs).
RESULTS: A monotonic time trend of survival was detected: a 2.6% lower risk of death for each increasing year over the past 30 years. Three prognostic factors had time-varying effects; the liver first metastasis (HR during the first 16 months of follow-up: 2.26; 95% confidence interval [CI], 1.65-3.11), the bone first metastasis (HR during the first 24 months of follow-up: 0.56; 95% CI, 0.43-0.74), and the disease-free interval (HR during the first 16 months of follow-up: 0.90; 95% CI, 0.85-0.95). The brain first metastasis, multiple first metastases, the lymph node ratio, and estrogen receptor status had a constant effect over time.
CONCLUSION: In our study we detected a constant time trend of improvement in prognosis of metastatic breast cancer patients over the past 30 years and identified prognostic factors with time-varying effects.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Disease-free interval; Outcome; Prognostic factors of survival; Site of metastasis; Time-varying effects

Mesh:

Year:  2017        PMID: 28988656     DOI: 10.1016/j.clbc.2017.08.012

Source DB:  PubMed          Journal:  Clin Breast Cancer        ISSN: 1526-8209            Impact factor:   3.225


  9 in total

Review 1.  Fracture risk assessment and clinical decision making for patients with metastatic bone disease.

Authors:  Timothy A Damron; Kenneth A Mann
Journal:  J Orthop Res       Date:  2020-03-23       Impact factor: 3.494

2.  Nomogram Predicts the Role of Primary Tumor Surgery on De Novo Stage-IV Breast Cancer Patients: A SEER-Based Competing Risk Analysis Model.

Authors:  Hanxiao Cui; Luyao Dai; Yuanhang Bao; Liqun Hu; Zhangjian Zhou; Meng Wang; Shuai Lin; Hao Wu; Xiaobin Ma; Huafeng Kang
Journal:  Front Oncol       Date:  2022-05-04       Impact factor: 5.738

3.  CORR Insights®: Is Total Femur Replacement a Reliable Treatment Option for Patients With Metastatic Carcinoma of the Femur?

Authors:  Adam S Levin
Journal:  Clin Orthop Relat Res       Date:  2018-05       Impact factor: 4.176

4.  Change in Survival in Metastatic Breast Cancer with Treatment Advances: Meta-Analysis and Systematic Review.

Authors:  Jennifer L Caswell-Jin; Sylvia K Plevritis; Lu Tian; Christopher J Cadham; Cong Xu; Natasha K Stout; George W Sledge; Jeanne S Mandelblatt; Allison W Kurian
Journal:  JNCI Cancer Spectr       Date:  2018-12-24

5.  Low Overall Survival in Women With De Novo Metastatic Breast Cancer: Does This Reflect Tumor Biology or a Lack of Access to Health Care?

Authors:  Leonardo R Soares; Ruffo Freitas-Junior; Maria P Curado; Regis R Paulinelli; Edesio Martins; José C Oliveira
Journal:  JCO Glob Oncol       Date:  2020-04

6.  New insights into patterns of first metastatic sites influencing survival of patients with hormone receptor-positive, HER2-negative breast cancer: a multicenter study of 271 patients.

Authors:  Jun Yamamura; Shunji Kamigaki; Junya Fujita; Hiroki Osato; Hironobu Manabe; Yumiko Tanaka; Wataru Shinzaki; Yukihiko Hashimoto; Yoshifumi Komoike
Journal:  BMC Cancer       Date:  2021-04-29       Impact factor: 4.430

7.  Clinicopathologic characteristics, metastasis-free survival, and skeletal-related events in 628 patients with skeletal metastases in a tertiary orthopedic and trauma center.

Authors:  Georg Herget; Babak Saravi; Eugenia Schwarzkopf; Mara Wigand; Norbert Südkamp; Hagen Schmal; Markus Uhl; Gernot Lang
Journal:  World J Surg Oncol       Date:  2021-02-25       Impact factor: 2.754

8.  Identification of Hub Genes to Regulate Breast Cancer Spinal Metastases by Bioinformatics Analyses.

Authors:  Yongxiong He; Yongfei Cao; Xiaolei Wang; Wu Jisiguleng; Mingkai Tao; Jianfeng Liu; Fei Wang; Lemeng Chao; Wenjun Wang; Pengfei Li; Haiping Fu; Wei Xing; Zhibo Zhu; Yanqiang Huan; Hongwei Yuan
Journal:  Comput Math Methods Med       Date:  2021-05-12       Impact factor: 2.238

9.  Development and application of a dynamic prediction model for esophageal cancer.

Authors:  Kunpeng Du; Lixian Li; Qi Wang; Jingwen Zou; Zhongjian Yu; Jiqiang Li; Yanfang Zheng
Journal:  Ann Transl Med       Date:  2021-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.